Navigation Links
Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments
Date:4/30/2009

Issuance of Canadian Patents 2,363,503 and 2,407,715 Strengthens Intellectual Property Position of Optherion's Novel Diagnostics for Age-Related Macular Degeneration

NEW HAVEN, Conn., April 30 /PRNewswire/ -- Optherion, Inc., a company developing novel molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that the Canadian Patent Office has granted patents 2,363,503 and 2,407,715.

The claims of the issued patents provide secure protection for diagnostic tests for determining the predisposition to AMD by screening for genetic modifications in several genes including complement factor H (CFH), complement factor B (CFB), complement factor 2 (C2) and complement factor 3 (C3) amongst others. Optherion has an exclusive worldwide license to these Canadian patent rights, the corresponding PCT patents and applications from the University of Iowa Research Foundation.

Colin J. Foster, Optherion's President and CEO, said: "The issuance of the Canadian patents is an important milestone in the development of our diagnostics business. With these and other patents pending, licensed from almost a dozen universities, we are well positioned to exclusively offer a range of predictive and prognostic diagnostic tests to healthcare professionals treating patients with AMD and other diseases of the alternative complement system. As we advance to commercialization, we will continue to develop and protect our intellectual property covering our novel products."

Optherion is developing a genetic test for AMD and is pursuing commercialization discussions with several providers within North American and international markets.

About Optherion:

Optherion, Inc. is a private, innovative biotechnology company that is developing protein therapeutics and molecular diagnostics for the management of dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on landmark scientific discoveries linking certain genes to AMD.


'/>"/>
SOURCE Optherion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Feb. 27, 2017 Pulmonary drug delivery market ... from USD 36.10 billion in 2016, at a CAGR ... pulmonary route as an alternate route of drug delivery, ... increasing incidence of respiratory diseases such as COPD, asthma, ... growth during the forecast period. However, emerging markets and ...
(Date:2/28/2017)... -- Clarivate Analytics marks the passing of one if its founding fathers, Dr. ... science in the service of scientific and scholarly research. A pioneer in ... that revolutionized the way researchers work with the literature, Garfield passed away ... ... Dr. Eugene Garfield, ...
(Date:2/28/2017)... Research and Markets has announced the addition of the ... their offering. ... The global digestive enzyme supplements market is expected ... regarding the severity of digestive disorders coupled with the need ... the forecast period. The increasing incidence of gastrointestinal tract diseases, ...
Breaking Medicine Technology:
(Date:2/28/2017)... , ... February 28, 2017 , ... Las Vegas Skin ... South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more than ... this clinic, located in the South Rancho neighborhood, has been renovated to provide medical ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... decade, has challenges as they transition from military to civilian life. Body image ... two million who experience poorer health and greater occurrence of chronic mental health ...
(Date:2/27/2017)... Houston, Texas (PRWEB) , ... February 27, 2017 ... ... leader in the alternative health care industry, announces Chris Brandl as its New ... has brought vision and purpose to corporations throughout his career. He began his ...
(Date:2/27/2017)... ... , ... The threat of nuclear warfare has long plagued this world. In ... underground testing of nuclear weapons. Years later, when her co-workers began dying, Dot started ... Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate ... and video system brings songs, movies, TV shows and much more apps for user ... high-definition sound. An immersive view of 1280 x 720 provides crisp images with remarkable ...
Breaking Medicine News(10 mins):